| Identification | More | [Name]
Cytidine 5'-monophosphate disodium salt | [CAS]
6757-06-8 | [Synonyms]
5'-CMP 2NA
5'-CYTIDYLIC ACID DISODIUM SALT
C-5'-P DISODIUM SALT
CMP DISODIUM SALT
CMP, NA2
CYTIDINE-5'-MONOPHOSPHATE DISODIUM SALT
CYTIDINE-5'-MONOPHOSPHATE SODIUM SALT
CYTIDINE-5'-MONOPHOSPHORIC ACID, DISODIUM
CYTIDINE 5'-PHOSPHATE, SODIUM SALT
CYTIDYLIC ACID DISODIUM SALT
Cytidine-5'-Monophosphoric Acid Disodium Salt
CYTIDINE 5'-MONOPHOSPHATE DISODIUMSIGMA GRADE
5'-cmp-na2
CMP-2Na
Cytidine 5'-monophosphate(CMP),2Na
5μ-CMP-Na2, 5μ-Cytidylic acid disodium salt
Cytidine 5μ-monophosphate hydrate disodium salt
C-5μ-P, CMP
Disodium 5’-cytidylate | [EINECS(EC#)]
229-819-3 | [Molecular Formula]
C9H12N3Na2O8P | [MDL Number]
MFCD00064355 | [Molecular Weight]
367.16 | [MOL File]
6757-06-8.mol |
| Chemical Properties | Back Directory | [Appearance]
White crystalline powder | [Melting point ]
300 °C | [refractive index ]
8 ° (C=2, H2O) | [storage temp. ]
2-8°C
| [form ]
crystalline
| [color ]
White | [InChI]
InChI=1/C9H14N3O8P.Na.H/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;;/h1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);;/t4-,6-,7-,8-;;/s3 | [InChIKey]
RCIPNLSOCXMZDD-RFFBCSJBNA-N | [SMILES]
O[C@@H]1[C@@H]([C@@H](COP(O)(O)=O)O[C@H]1N1C=CC(N)=NC1=O)O.[NaH] |&1:1,2,3,11,r| | [CAS DataBase Reference]
6757-06-8(CAS DataBase Reference) |
| Questions And Answer | Back Directory | [Uses]
Cytidine 5'-Monophosphate Disodium Salt is a salt form of Cytidine 5'-Monophosphate, a constituent of nucleic acids that has been isolated from yeast nucleic acid. |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes .
S37/39:Wear suitable gloves and eye/face protection .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [F ]
1-10 | [HS Code ]
29349990 |
| Hazard Information | Back Directory | [Description]
Cytidine 5'-monophosphate disodium salt (5'-CMPNa2,6757-06-8) is an organic sodium salt that can be used as a pharmaceutical active ingredient. 5'-CMPNa2 can be used with UMP-Na2, vitamin B6, lipoic acid, and magnesium lactate dihydrate to prepare a capsule-type compound drug for the treatment of polyneuropathy[1].
| [Chemical Properties]
White crystalline powder | [Definition]
ChEBI: An organic sodium salt that is the disodium salt of CMP. | [Production Methods]
The production method of Cytidine 5'-monophosphate disodium salt(6757-06-8) comprises the following steps: a. adding cytidine, triethyl phosphate and pyridine into a reaction container respectively, and adjusting the reaction temperature to -15-5°C after mixing evenly, and slowly adding a certain amount of phosphorus oxychloride under the temperature condition, and continuing to stir and react for 10-30h after adding; b. taking samples for HPLC analysis, and when the conversion rate is ≥99%, adding 10-15% ice salt water for hydrolysis, and the hydrolysis temperature is controlled to be 0-5°C, and the hydrolysis time is 10-20h; c. after the hydrolysis is completed, standing and stratifying, removing the organic phase, and obtaining a water layer for standby use; d. adjusting the pH of the water layer to 7.0-8.0 with 30% sodium hydroxide, and then dripping 95% alcohol twice the volume of the solution, precipitating crystals, and filtering to obtain a crude product. e. dissolving the crude product, adding activated carbon for decolorization, and continuing to drip 95% alcohol twice the volume of the solution to precipitate crystals, filtering, rinsing, and drying to obtain the finished product Cytidine 5'-monophosphate disodium salt.
| [Biochem/physiol Actions]
Cytidine monophosphate?(CMP) serve as a nucleotide?carrier for sugars. | [References]
[1] M. ALMAKAIEV L. S O Bashura. The risk assessment of the combined medicine in the capsule dosage form at the pharmaceutical development stage[J]. News of Pharmacy, 2021. DOI:10.24959/nphj.21.54. |
|
|